A new study suggests that semaglutide, a drug commonly used to treat diabetes, may help protect the brain from the effects of ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss.

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...